NCT05530577View on ClinicalTrials.gov

Effects of Semaglutide on Nicotine Intake

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions

Tobacco Use DisorderNicotine Addiction

Interventions

DRUG

Semaglutide

Semaglutide (subcutaneous)

DRUG

Sham/placebo

Sham subcutaneous injection

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of North Carolina, Chapel Hill

OTHER